Addressing Stigma Surrounding MDMA and Psychedelic Therapies, with Gus Alva, MD
In this part of our 5-part series, Gus Alva, MD highlights the importance of education and overcoming skepticism about MDMA-assisted therapy.
Interpreting Trial Data for MDMA-Assisted Therapy, with Gus Alva, MD
In this part of our 5-part series, Gus Alva, MD talks about MDMA's efficacy in controlled settings and addresses misconceptions.
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X
Presented at ASRS 2024, late-breaking RHONE-X data shows more than 90% of patients experienced the absence of DME after four years of faricimab.
Dilraj Grewal, MD: Development of MNV in Geographic Atrophy in GATHER Trials
Eyes with GA that developed MNV in the GATHER trials experienced a slower growth rate with avaincaptad pegol than with sham treatment.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy
Patients treated with PDS with ranibizumab refilled every nine months maintained vision improvements and experienced consistent safety over two years.
Carl C. Awh, MD: Two-Year Outcomes of the Port Delivery System for DME
Over 2 years, the Port Delivery System demonstrated continued efficacy with fixed refill-exchange procedures every 24 weeks in the Phase 3 Pagoda trial.
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort
Interim results from the PRISM population extension cohort found that 4D-150 was well tolerated and reduced the mean annualized anti-VEGF injection rate.
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD
A single Ixo-vec injection showed up to a 95% reduction in annualized anti-VEGF injections, according to first-time 26-week results from the Phase 2 LUNA study.
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry
Pegcetacoplan for 36 months led to fewer absolute scotomatous points on microperimetry than delayed treatment, suggesting its efficacy in preserving vision.
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD
RGX-314 produced by the NAVXpress platform process showed a similar clinical profile to the adherent cell culture process in this Phase 2 pharmacodynamic study.
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression
Katherine Talcott, MD describes a posthoc analysis of the GATHER trials showing how imaging biomarkers of photoreceptor structure predict GA growth.
Veeral Sheth, MD: Assessing EYP-1901 Supplemental Injection Use in Wet AMD
Veeral Sheth, MD describes an assessment of the need for supplemental injection use after EYP-1901 for wet AMD.
Raj Chovatiya, MD, PhD: Discussing the FDA Approval of Roflumilast for Atopic Dermatitis
In this interview, Chovatiya discussed the recent FDA approval of roflumilast cream 0.15% for patients with eczema aged 6 years and older.
Concluding Thoughts on Elamipretide in Dry AMD Patients with GA
Arshad Khanani, MD shares his excitement about the potential of elamipretide joining the treatment armamentarium in GA and his final thoughts on the topic.
What Does Elamipretide Represent in Dry AMD Patients with GA?
Arshad Khanani, MD points to the viability of the mechanism of action of elamipretide for geographic atrophy in dry AMD, and what it could represent for patient outcomes.
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials
Arshad Khanani, MD provides insight into the pivotal Phase 3 clinical trials investigating elamipretide for geographic atrophy in dry AMD.
Elamipretide in the Phase 2 ReCLAIM-2 Trial
Arshad Khanani, MD discusses the key findings on elamipretide from the Phase 2 ReCLAIM-2 clinical trial.
Mechanism of Action of Elamipretide in Dry AMD Patients with GA
Arshad Khanani, MD describes the mechanism of action of elamipretide, an investigational product candidate for geographic atrophy in dry age-related macular degeneration.
Establishing the Treatment Landscape in Geographic Atrophy
Arshad Khanani, MD breaks down the current treatment options for geographic atrophy and provides insight into the therapeutic pipeline.
A Promising Pipeline for COPD
Mannino, Anzueto and Christenson conclude the panel with thoughts on developing biologics for COPD, and increased interest in the field after ensifentrine and dupilumab.
Projecting Dupilumab's Fit in COPD
Ahead of the anticipated FDA decision in September, an expert panel reviews the promising data and unique role dupilumab may have in COPD.
What the Ensifentrine FDA Approval Means for COPD
In this HCPLive Special Report, experts review ensifentrine's role as a novel maintenance therapy for COPD.
CATALYST Raises Red Flag on Hypercortisolism in Type 2 Diabetes, with Ralph DeFronzo, MD
Ralph DeFronzo, MD, discusses the results of the first phase of the CATALYST trial and how results should influence the care of patients with difficult-to-treat type 2 diabetes.
Signs and Symptoms of Connective Tissue Disease
Amanda Mixon, PA-C, discusses how rheumatic diseases may first present in skin, ocular or gastric symptoms.
What to Know About Cannabis Use and Diabetes, with Halis Akturk, MD
Halis Akturk, MD, offers an overview of the growing prevalence and dangers associated with cannabis use among patients with type 1 diabetes.
Timothy Garvey, MD: Drivers of Differences in Weight Loss with Incretins Based on Diabetes Status
Details of an analysis from ADA 2024 compared matched cohorts from SURMOUNT-1 and SURMOUNT-2 to determine drivers of differences in weight loss from the trials.
Connective Tissue Disease Brings Dermatology & Rheumatology Together
Amanda Mixon, PA-C, discusses the need to better bridge the rheumatology and dermatology care teams due to overlapping diseases.
What Makes JAK Inhibitors Safe in Dermatology
Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.
Potential JAK Inhibitor Combination Regimens in Dermatology
Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.
Therapies in Development for Hidradenitis Suppurativa
Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.
